Clene Inc. Files 8-K, Reports Other Events

TL;DR

Clene Inc. filed an 8-K on Dec 10, 2024, updating corporate info and financials.

AI Summary

Clene Inc. filed an 8-K on December 10, 2024, to report on other events and financial statements. The filing indicates a name change from Chelsea Worldwide Inc. to Clene Inc. on August 27, 2020, and provides details about its principal executive offices in Salt Lake City, Utah.

Why It Matters

This filing provides an update on Clene Inc.'s corporate status and administrative details, which is important for investors to track company changes.

Risk Assessment

Risk Level: low — The filing is primarily administrative and does not appear to contain significant new financial or operational information that would immediately impact risk.

Key Players & Entities

• Clene Inc. (company) — Registrant
• Chelsea Worldwide Inc. (company) — Former company name
• August 27, 2020 (date) — Date of name change
• December 10, 2024 (date) — Date of report
• Salt Lake City, Utah (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value CLNN The Nasdaq Capital M
• $230.00 — rtieth of one share of Common Stock for $230.00 per share CLNNW The Nasdaq Capital

Filing Documents

• clnn20241209_8k.htm (8-K) — 31KB
• ex_755093.htm (EX-99.1) — 19KB
• ex_755094.htm (EX-99.2) — 1KB
• ex_755095.htm (EX-99.3) — 1KB
• ex_755096.htm (EX-99.4) — 31KB
• slide01.jpg (GRAPHIC) — 126KB
• slide02.jpg (GRAPHIC) — 269KB
• slide03.jpg (GRAPHIC) — 169KB
• slide04.jpg (GRAPHIC) — 157KB
• slide05.jpg (GRAPHIC) — 112KB
• slide06.jpg (GRAPHIC) — 143KB
• slide07.jpg (GRAPHIC) — 156KB
• slide08.jpg (GRAPHIC) — 159KB
• slide09.jpg (GRAPHIC) — 146KB
• slide10.jpg (GRAPHIC) — 152KB
• slide11.jpg (GRAPHIC) — 171KB
• slide12.jpg (GRAPHIC) — 137KB
• slide13.jpg (GRAPHIC) — 147KB
• slide14.jpg (GRAPHIC) — 91KB
• slide15.jpg (GRAPHIC) — 153KB
• slide16.jpg (GRAPHIC) — 91KB
• slide17.jpg (GRAPHIC) — 142KB
• slide18.jpg (GRAPHIC) — 165KB
• slide19.jpg (GRAPHIC) — 102KB
• slide20.jpg (GRAPHIC) — 161KB
• slide21.jpg (GRAPHIC) — 176KB
• slide22.jpg (GRAPHIC) — 183KB
• slide23.jpg (GRAPHIC) — 165KB
• slide24.jpg (GRAPHIC) — 156KB
• slide25.jpg (GRAPHIC) — 184KB
• slide26.jpg (GRAPHIC) — 153KB
• slide27.jpg (GRAPHIC) — 152KB
• slide28.jpg (GRAPHIC) — 136KB
• slide29.jpg (GRAPHIC) — 238KB
• slide30.jpg (GRAPHIC) — 61KB
• slide31.jpg (GRAPHIC) — 631KB
• slide32.jpg (GRAPHIC) — 539KB
• 0001437749-24-037061.txt ( ) — 8124KB
• clnn-20241210.xsd (EX-101.SCH) — 4KB
• clnn-20241210_def.xml (EX-101.DEF) — 14KB
• clnn-20241210_lab.xml (EX-101.LAB) — 18KB
• clnn-20241210_pre.xml (EX-101.PRE) — 14KB
• clnn20241209_8k_htm.xml (XML) — 5KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. In connection with the press release discussed under Item 8.01 in this Current Report on Form 8-K (the "Current Report"), on December 10, 2024, Clene Inc. (the "Company") released an updated corporate presentation (the "Corporate Presentation") on its website, invest.clene.com. A copy of the Corporate Presentation is furnished as Exhibit 99.1 to this Current Report and is incorporated herein by reference. The Company plans to use its website to disseminate future updates to the Corporate Presentation and may not file or furnish a Current Report on Form 8-K alerting investors if the Corporate Presentation is updated. Additionally, in poster sessions at the 35th International Symposium on ALS/MND on December 6, 2024 and December 7, 2024, the Company presented additional data from its clinical trials and expanded access programs in amyotrophic lateral sclerosis ("ALS"), including (i) data on long-term survival with CNM-Au8 30 mg treatment and (ii) biomarkers of neurodegeneration, astrogliosis, and inflammation. Copies of the posters are furnished as Exhibit 99.2 and 99.3 to this Current Report and are incorporated herein by reference. The information furnished in this Item 7.01, including Exhibit 99.1, Exhibit 99.2, and Exhibit 99.3, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), as amended, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in any such filings, except as shall be expressly set forth by specific reference in such a filing.

01 Other Events

Item 8.01 Other Events. On December 10, 2024, the Company issued a press release announcing the U.S. Food and Drug Administration ("FDA") provided a potential path for an accelerated approval through submission of additional CNM-Au8 biomarker data in ALS. A copy of the press release is filed as Exhibit 99.4 to this Current Report and is incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Corporate presentation. 99.2 Long-term survival poster. 99.3 ALS biomarker poster. 99.4 Press release, dated December 10, 2024, announcing FDA provides roadmap for accelerated approval pathway through submission of additional CNM-Au8 biomarker data in ALS. 104 Cover Page Interactive Data File (formatted as Inline XBRL). 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. CLENE INC. Date: December 10, 2024 By: /s/ Robert Etherington Robert Etherington President and Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR